Literature DB >> 15929175

Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer.

Eeva Salminen1, Salla Palmu, Tero Vahlberg, Peter-J Roberts, Karl-Owe Söderström.   

Abstract

AIM: To assess the expression of Ki67 as prognosticator in rectal/recto sigmoid cancer.
METHODS: Samples from 146 patients with rectal and recto sigmoid cancer were studied for expression of Ki67 and its prognostic significance in comparison with clinico-pathological predictors of survival. Formalin-fixed, paraffin-embedded tissues from 6 (4.1%) patients with T1, 26 (17.8%) with T2, 94 (64.4%) with T3, and 20 (13.7%) with T4 tumors were studied. Ki67 expression was determined immunohistochemically. Samples were divided according to mean value into high (>40%) and low (< or =40%) expression. Areas of extensive proliferation (>50%) were defined as "hot spot" areas.
RESULTS: Hot spot areas were present in samples regardless of histopathological grade. Lower TNM and Dukes stage and higher expression of Ki67 and presence of Ki67 hot spot areas in histopathological samples were associated with better survival, whereas no association was observed with histopathological grade (P = 0.78). In Cox multivariate regression analysis, significant prognostic factors were Dukes stage (P<0.001), presence of lymph node metastases (P = 0.015), age (P = 0.035) and presence of Ki67 hot spot areas (P = 0.044).
CONCLUSION: Proliferative activity as measured by Ki67 in rectal cancer is associated with survival improvement compared with patients with low Ki67. Areas of prognostically significant increased proliferation were found independently of histopathological tumor grade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929175      PMCID: PMC4316056          DOI: 10.3748/wjg.v11.i21.3245

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count.

Authors:  J J Isola; H J Helin; M J Helle; O P Kallioniemi
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

Review 2.  Rectal carcinoma, type of surgery and the role of adjuvant radiation therapy.

Authors:  L Påhlman
Journal:  Ann Chir Gynaecol       Date:  1993

3.  Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer.

Authors:  T Kimura; S Tanaka; K Haruma; K Sumii; G Kajiyama; F Shimamoto; N Kohno
Journal:  Int J Oncol       Date:  2000-01       Impact factor: 5.650

4.  Tumor proliferation in rectal cancer following preoperative irradiation.

Authors:  C G Willett; G Warland; M P Hagan; W J Daly; J Coen; P C Shellito; C C Compton
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

5.  [Influence of rectal preparation by enema on cell proliferation in the normal rectal mucosa in man].

Authors:  T Lehy; J L Abitbol; M Mignon
Journal:  Gastroenterol Clin Biol       Date:  1984-03

6.  Monoclonal antibody JC1: new reagent for studying cell proliferation.

Authors:  M C Garrido; J L Cordell; M H Becker; G Key; J Gerdes; M Jones; K C Gatter; D Y Mason
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

7.  Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations.

Authors:  Eva Fernebro; Pär-Ola Bendahl; Michael Dictor; Annette Persson; Mårten Fernö; Mef Nilbert
Journal:  Int J Cancer       Date:  2004-10-10       Impact factor: 7.396

8.  Positivity of the proliferation marker Ki-67 in noncycling cells.

Authors:  M G van Oijen; R H Medema; P J Slootweg; G Rijksen
Journal:  Am J Clin Pathol       Date:  1998-07       Impact factor: 2.493

9.  Colorectal cancer staging as a prognostic feature.

Authors:  O H Beahrs
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

10.  The Ki67 index a prognostic marker in medullary thyroid carcinoma.

Authors:  L E Tisell; A Oden; A Muth; G Altiparmak; J Mõlne; H Ahlman; O Nilsson
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more
  19 in total

1.  Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation.

Authors:  Nara Rosana Andrade; Celina Tizuko Fujiyama Oshima; Thiago Simão Gomes; Ricardo Artigiani Neto; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-03

2.  Combined analysis of biomarkers of proliferation and apoptosis in colon cancer: an immunohistochemistry-based study using tissue microarray.

Authors:  M S Reimers; E C M Zeestraten; T C van Alphen; J W T Dekker; H Putter; S Saadatmand; G J Liefers; C J H van de Velde; P J K Kuppen
Journal:  Int J Colorectal Dis       Date:  2014-06-21       Impact factor: 2.571

3.  Prognostic significance of AEG-1 expression in colorectal carcinoma.

Authors:  Hongtao Song; Cong Li; Rui Li; Jingshu Geng
Journal:  Int J Colorectal Dis       Date:  2010-07-13       Impact factor: 2.571

4.  Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Authors:  Alan P Venook; Donna Niedzwiecki; Margarita Lopatin; Xing Ye; Mark Lee; Paula N Friedman; Wendy Frankel; Kim Clark-Langone; Carl Millward; Steven Shak; Richard M Goldberg; Najjia N Mahmoud; Robert S Warren; Richard L Schilsky; Monica M Bertagnolli
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

5.  Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.

Authors:  Li Bian; Tao Wang; Shao-Hua Zhang; Hui-Qiang Zhang; Yun-Fei Guo; Ge Du; Wang Li; Shi-Kai Wu; San-Tai Song; Ze-Fei Jiang
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

6.  Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.

Authors:  Piotr Daniel; Malgorzata Wagrowska-Danilewicz; Marian Danilewicz; Olga Stasikowska; Ewa Malecka-Panas
Journal:  Int J Colorectal Dis       Date:  2007-03-30       Impact factor: 2.571

7.  Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.

Authors:  Shibao Li; Zhiyuan Wu; Yuming Chen; Zhihua Kang; Hua Wang; Ping He; Xinju Zhang; Tingting Hu; Qunfeng Zhang; Yanqun Cai; Xiao Xu; Ming Guan
Journal:  Tumour Biol       Date:  2015-11-11

8.  Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.

Authors:  Kim M Clark-Langone; Chithra Sangli; Jayadevi Krishnakumar; Drew Watson
Journal:  BMC Cancer       Date:  2010-12-23       Impact factor: 4.430

9.  Securin promotes the identification of favourable outcome in invasive breast cancer.

Authors:  K Talvinen; H Karra; S Hurme; M Nykänen; A Nieminen; J Anttinen; T Kuopio; P Kronqvist
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

10.  The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer.

Authors:  Zhenyu He; Chuanbing Shi; Hao Wen; Fanglong Li; Baolin Wang; Jie Wang
Journal:  J Biomed Res       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.